

**Differential Diagnosis of
Parkinson's Disease,
Essential Tremor, and
Multiple Sclerosis**

Greg Pontone, MD, MHS

1

Title & Affiliation

Greg Pontone, MD, MHS
 Director, Parkinson's Neuropsychiatry Clinical Programs
 Johns Hopkins University School of Medicine

2

Disclosures

Dr. Pontone has consulted for:

- Acadia Pharmaceuticals Inc
- Concert Pharmaceuticals
- Cerevance

3

Learning Objectives

- Summarize the most common clinical presentations of multiple sclerosis, Parkinson's disease, and essential tremor
- Discuss the differential diagnosis of these three neurological disorders
- Briefly review general treatment strategies and disease modifying therapies

4

Multiple Sclerosis

5

Multiple Sclerosis

- Incidence and prevalence are increasing globally
- Nearly 3:1 female to male
- Mechanism remains unclear, gene-environment interaction suspected, 1/8 have family history
- Low serum vitamin D, ultraviolet B light, smoking, (childhood) obesity, and infection with Epstein-Barr virus are associated with increased risk
- Migration studies suggest time from exposure to risk factors and onset is 10-20 years
- Organ specific T-cell mediated autoimmune disease
- Two-stage disease with early inflammation responsible for relapsing-remitting disease and delayed neurodegeneration causing non-relapsing progression



6

Diagnosing Multiple Sclerosis

- Diagnosis is clinical, excluding mimics is key
- Characteristic pathological hallmark of MS is perivenular inflammatory lesions, leading to demyelinating plaques
- Oligodendrocyte damage and demyelination occur as a result of inflammation
- Most common presentations are optic neuritis, brainstem, and spinal cord syndromes
- MS relapses develop over hours to days and last several weeks, with gradual recovery in early disease
- Neuronal reserve is lost over repeat relapses, recovery is incomplete, neurological deficits accrue resulting in increasing disability; MRI often shows brain volume loss compared to controls

7

MRI of Multiple Sclerosis Lesions



8

Multiple Sclerosis Subtypes

- Relapsing and remitting multiple sclerosis (RRMS) ~85%
- Secondary progressive multiple sclerosis – develops 10-15 years after RRMS onset in ½
- Primary progressive multiple sclerosis (PPMS) ~10% – progressive disability in one dominant neuronal system (progressive spastic paraparesis, but sensory ataxia, cerebellar ataxia, cognitive and progressive visual failure)
- Neurodegeneration is likely present from clinical onset
- Alternatively, MS as a continuum from radiologically isolated to relapsing to progressive disease

9

Diagnosing Multiple Sclerosis – Relapsing-Remitting (MacDonald 2017)

Dissemination in space

- 2 or more lesions or 1 lesion with history of a prior attack involving a different CNS site or,
- One or more T2 lesion in at least 2 of 4 MS-typical regions of the CNS

Dissemination in time

- 2 or more attacks separated by at least 1 month, or
- Simultaneous presence of asymptomatic gadolinium enhancing and non-enhancing lesions at any time, or
- New T2 and/or gad-enhancing lesion on follow up compared to baseline, or
- Demonstration of CSF-specific oligoclonal bands

10

Diagnosing Multiple Sclerosis – Primary Progressive (Macdonald 2010)

- 1) 1 year of disease progression and
- 2) 2 out of 3:
 - Diffusion in space in brain, 1 or more T2 lesions in at least one MS-typical region
 - Diffusion in space in the spinal cord, 2 or more T2 lesions in the cord
 - Positive CSF, oligoclonal bands on isoelectric focusing and/or elevated IgG index

11

Differential Diagnosis of Multiple Sclerosis

Autoimmune disorders:
Behcet syndrome, CNS vasculitis, sarcoidosis, systemic lupus, Sjogren syndrome

Hereditary disorders:
adrenoleukodystrophy, Refsum disease, spinocerebellar degeneration, CADASIL

Infectious causes: CMV, HIV, human T-lymphotropic virus type 1, HSV, varicella zoster virus, Lyme, syphilis, tuberculosis

Toxic/nutritional syndromes: alcohol, B12, methylmalonic acid, plasma homocysteine, folate

Vascular ischemic event: stroke, TIA, AVM or fistula for spinal, ischemic optic neuritis

12

Differential Diagnosis of Multiple Sclerosis

- Neuromyelitis optica (NMO)
- Presents with inflammation and demyelination
- Most commonly optic neuritis and transverse myelitis
- Similar to MS may relapse, but little to no progression independent of relapses
- 10:1 women to men; more common in African Americans, Asians, Hispanics
- Criteria for with and without IgG to aquaporin-4 water channel; seropositivity in 75% of patients with NMO clinical symptoms

13

Differential Diagnosis of Multiple Sclerosis

- Diagnostic lumbar puncture is advised, oligoclonal immunoglobulin G bands or oligoclonal bands
- Anti-nuclear antibody, B12, thyroid function, RPR, HIV at a minimum
- MRI brain and spinal cord if consistent with presentation

14

Treatments for Multiple Sclerosis

- Disease-modifying therapies
 - 1) Immunosuppressant — fingolimod, natalizumab, ocrelizumab
 - 2) Immunomodulatory — interferon beta, glatiramer acetate, teriflunomide
 - 3) Immune reconstitution therapies --- alemtuzumab and cladribine
- No evidence of disease activity (NEDA)
- Symptomatic therapies
 - Medications and physical therapies for symptoms resulting from CNS damage, eg, medications for bladder dysfunction, medications for neuropathic pain, Sativex for spasticity, fampridine for gait disturbance

15


Parkinson's Disease

16

Parkinson's Disease

- Parkinson's disease is a progressive neurodegenerative disorder characterized by aggregates of misfolded α -synuclein called Lewy bodies
- Parkinson's disease has a complex clinical phenotype that includes motor and non-motor symptoms that vary not only in severity but also in terms of presence or absence from case to case

17



18

Clinical Diagnosis of PD Requires Only Motor Symptoms


- First essential criterion:
 - Slowing of physical movement (bradykinesia)
- Plus at least one of the following:
 - Tremor (4-7hz)
 - Muscle rigidity

Postuma RB et al Mov Disord 2015

19

19

Differential Diagnosis of Parkinsonism



20

Atypical Parkinsonism – Degenerative

α synucleinopathies

- Multiple system atrophy
- Lewy body dementia


Tauopathies

- Progressive supranuclear palsy
- Corticobasal syndrome
- Other 4 repeat tauopathies

❖ Spinocerebellar ataxias (other proteins, CAG repeats) may also be in the differential

21

Secondary Parkinsonism



22

Differential Diagnosis of Parkinsonism – ‘Absolute Exclusion Criteria’

1. Unequivocal cerebellar abnormalities – cerebellar gait or oculomotor changes, limb ataxia
2. Downward vertical supranuclear gaze palsy or slowing of downward saccades
3. Diagnosis of probable bvFTD or primary progressive aphasia within 5 years of disease
4. Parkinsonism restricted to lower limbs for more than 3 years
5. Use of dopamine receptor blocker or dopamine-depleting agent
6. Absence of response to high-dose levodopa despite at least moderate severity disease
7. Unequivocal cortical sensory loss, clear limb apraxia, or progressive aphasia
8. Normal functional neuroimaging of the presynaptic dopaminergic system
9. Alternative condition is more likely

23

Differential Diagnosis of Parkinsonism – Red Flags

1. Rapid progression of gait impairment, eg, wheelchair within 5 year onset
2. Absence of progression of motor symptoms
3. Early bulbar dysfunction, severe dysphonia or dysarthria or dysphagia within 5 year onset
4. Inspiratory respiratory dysfunction: either diurnal or nocturnal inspiratory stridor
5. Severe autonomic failure in first 5 years
6. Recurrent falls because of impaired balance within 3 year onset
7. Disproportionate anterocollis or contractures of hand or feet within first 10 year
8. Absence of any common nonmotor features despite 5 year disease duration
9. Otherwise unexplained pyramidal tract signs, defined as pyramidal weakness, hyperreflexia
10. Bilateral symmetric parkinsonism

24

Interventions for Parkinson's Disease

1. Prevention or delay of disease progression ('disease modifying')
2. Symptomatic monotherapy
3. Adjunctive therapies
4. Prevent or delay of motor complications
5. Motor complication therapies

25

Disease Modifying Interventions

- Exercise – has insufficient evidence and considered investigational, but is widely recommended
- No clinically useful interventions to prevent or delay disease progression (Fox SH et al 2018)
- Notable negative studies – MAOIs, CoQ10, creatine, vitamin D, dopamine agonists
- Promising candidates – BIIB054 (cinpanemab) targets abnormal alpha-synuclein, BIIB094 (LRRK2 ASO) antisense oligonucleotide helps reduce LRRK2 protein, small molecules may also be helpful, agents that down regulate inflammation especially via type-2 astrocytes

26

Symptomatic Monotherapy


Efficacious – clinically useful

- Dopamine agonists – non-ergot, ergot
- Levodopa + peripheral decarboxylase inhibitor – immediate release, controlled release, extended release
- Monoamine oxidase inhibitors – B-selective, eg, rasagiline, selegiline

Likely efficacious – clinically useful or possibly useful

- Anticholinergics
- Amantadine

27



28

Essential Tremor

29

Essential Tremor

- Essential tremor is the most common movement disorder affecting ~1% of the population
- Prevalence increases 5-fold with age; but does occur in children and young adults
- ET is autosomal dominant in at least 60% of patients

30

Diagnosis of Essential Tremor

- Isolated 'action' tremor 6-12 Hz of bilateral upper limbs of at least 3 years duration
- 'Action tremor' – postural or kinetic tremor involuntary, rhythmic, oscillatory movement of a body part when maintaining posture or with voluntary movement
- May be accompanied by tremor of head, voice, or lower limbs (less common)
- 'Isolated' no other neurologic signs, such as ataxia or parkinsonism
- Amplitude of the kinetic tremor remains constant between targets
- Tremor often temporarily improves with alcohol

31

Differential Diagnosis of Essential Tremor

- Parkinson's disease
- Drug induced tremor
- Hyperthyroidism
- Wilson's disease (under age 50)


32

Differential Diagnosis of Essential Tremor


- | | |
|--------------------------------------|----------------------------------|
| Essential Tremor | Parkinson's Disease |
| • Family history in >60% | • Family history 5%-15% |
| • Tremor improves with alcohol | • Alcohol does not help tremor |
| • Action tremor | • Rest tremor |
| • Tremor onset is bilateral | • Onset is unilateral |
| • Associated signs absent | • Will have bradykinesia, others |
| • Tremor absent/reduced when walking | • Tremor when walking |
| • Negative DaTscan* | • Positive DaTscan |

33


A



B




C



Differential
Diagnosis
of Essential
Tremor

Stephen G Reich, Med Clin N Am 103 (2019) 351-356

34



Normal Scan
"Comma"-shaped
Possible essential tremor

Abnormal Scan
"Period"-shaped
Possible parkinsonian syndrome

DaTscan
– SPECT
ioflupane
I-123

35

Interventions for Essential Tremor

- Education and reassurance may be sufficient for mild cases without significant functional impairment
- Best-evidence level A: propranolol and primidone (other beta-blockers have less evidence)
- Level B gabapentin, topiramate, and alprazolam
- Level C clonazepam, nimodipine, and limb injections of botulinum toxin
- Disabling tremor refractory to medical therapy, consider deep brain stimulation ventral intermediate nucleus of the thalamus (VIM) or focused ultrasound of VIM

36



37

References

- Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. *JAMA*. 2020 Feb 11;323(6):548-560. doi: 10.1001/jama.2019.22360. PMID: 32044947.
- Dobson R, Giovannoni G. Multiple sclerosis - a review. *Eur J Neurol*. 2019 Jan;26(1):27-40. doi: 10.1111/ene.13819. Epub 2018 Nov 18. PMID: 30300457.
- Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. *Mov Disord*. 2015 Oct;30(12):1591-601. doi: 10.1002/mds.26424. PMID: 26474316.
- Reich SG, Savitt JM. Parkinson's Disease. *Med Clin North Am*. 2019 Mar;103(2):337-350. doi: 10.1016/j.mcna.2018.10.014. Epub 2018 Dec 3. PMID: 30704685.

38
